Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
V Ambrosini, J Kunikowska, E Baudin, L Bodei… - European journal of …, 2021 - Elsevier
Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society
JR Howe, K Cardona, DL Fraker, E Kebebew… - Pancreas, 2017 - journals.lww.com
Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the
past decades, and are now the most common type of small bowel tumor. Consequently …
past decades, and are now the most common type of small bowel tumor. Consequently …
[HTML][HTML] Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Pavel, K Öberg, M Falconi, EP Krenning, A Sundin… - Annals of …, 2020 - Elsevier
Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …
may occur at many different disease sites. Most frequently, these neoplasms occur in the …
ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging
A Sundin, R Arnold, E Baudin, JB Cwikla… - …, 2017 - karger.com
Contrast-enhanced computed tomography (CT) of the neck-thorax-abdomen and pelvis,
including 3-phase examination of the liver, constitutes the basic imaging for primary …
including 3-phase examination of the liver, constitutes the basic imaging for primary …
Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors
TA Hope, EK Bergsland, MF Bozkurt… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …
Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
Gallium 68 (68Ga) 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)–
octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography …
octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography …
Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT
Y Sanli, I Garg, A Kandathil, T Kendi… - American Journal of …, 2018 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to provide a review of the use of 68Ga
tetraazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a …
tetraazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a …
Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors
Our purpose was to evaluate the safety and efficacy of 68Ga-DOTATATE PET/CT compared
with 111In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and …
with 111In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and …
68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic …
Neuroendocrine tumors (NETs) are uncommon tumors with increasing incidence and
prevalence. Current reports suggest that 68Ga-DOTATATE PET/CT imaging improves …
prevalence. Current reports suggest that 68Ga-DOTATATE PET/CT imaging improves …
The impact of somatostatin receptor–directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis
M Barrio, J Czernin, S Fanti, V Ambrosini… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …